The NHS could reportedly save £4m a year by offering women with low-risk breast cancer-a genetic test which helps preclude the use of overtreatment and its associated toxicities.

Primarily, the test called Prosigna is currently only licensed for use in post-menopausal breast cancer that has spread to no more than three lymph nodes. According to experts at University College London, offering the test to women as young as 40 could save the........

© The News International